Darren M Brenner, Satish Sc Rao, Bryan Curtin, Eamonn Quigley
{"title":"Real -World Evidence of the Long-Term Clinical Utility of a Vibrating Capsule in the Management of Chronic Idiopathic Constipation.","authors":"Darren M Brenner, Satish Sc Rao, Bryan Curtin, Eamonn Quigley","doi":"10.14309/ctg.0000000000000918","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacological therapies for chronic idiopathic constipation (CIC) are useful, but many patients report dissatisfaction from a lack of efficacy and occurrence of adverse events. The vibrating capsule (VC) is an FDA approved non-pharmacologic, treatment for CIC. However, its long-term usefulness in a community setting is unknown. The goal of this study was to assess the long-term efficacy and safety of vibrating capsule treatment in a real-world community setting.</p><p><strong>Methods: </strong>We conducted a post-marketing analysis of CIC patients prescribed VC who completed at least 3 or 6 months of treatment. The clinical utility was assessed via patient reported symptoms in an electronic stool diary. Safety data was also collected.</p><p><strong>Results: </strong>1722 patients were prescribed VC, and 491 and 298 took the VC and kept stool diaries for 3 and 6 months respectively. Approximately 46% of patients were >55 years of age and 85% were women. Compared to baseline, complete spontaneous bowel movement (CSBM) rates increased significantly throughout the 3 and 6 -month periods (average increase of >1 CSBM per week; P< 0.0001). Mean stool consistency (Bristol Stool Form Scale) improved from 2.9 (baseline) to 4.1 during treatment (P<0.0001), mean straining effort (1-4) decreased from 2.9 to 1.6 (P<0.0001), and toileting time also significantly decreased (P<0.0001). Safety analysis revealed that 4.6% of patients reported feeling a sensation of vibration, 1.8% reported abdominal pain and 0.64% reported diarrhea.</p><p><strong>Conclusions: </strong>In a community setting, the VC appears both effective and safe for long term treatment of chronic constipation with diarrhea being notably uncommon.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000918","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pharmacological therapies for chronic idiopathic constipation (CIC) are useful, but many patients report dissatisfaction from a lack of efficacy and occurrence of adverse events. The vibrating capsule (VC) is an FDA approved non-pharmacologic, treatment for CIC. However, its long-term usefulness in a community setting is unknown. The goal of this study was to assess the long-term efficacy and safety of vibrating capsule treatment in a real-world community setting.
Methods: We conducted a post-marketing analysis of CIC patients prescribed VC who completed at least 3 or 6 months of treatment. The clinical utility was assessed via patient reported symptoms in an electronic stool diary. Safety data was also collected.
Results: 1722 patients were prescribed VC, and 491 and 298 took the VC and kept stool diaries for 3 and 6 months respectively. Approximately 46% of patients were >55 years of age and 85% were women. Compared to baseline, complete spontaneous bowel movement (CSBM) rates increased significantly throughout the 3 and 6 -month periods (average increase of >1 CSBM per week; P< 0.0001). Mean stool consistency (Bristol Stool Form Scale) improved from 2.9 (baseline) to 4.1 during treatment (P<0.0001), mean straining effort (1-4) decreased from 2.9 to 1.6 (P<0.0001), and toileting time also significantly decreased (P<0.0001). Safety analysis revealed that 4.6% of patients reported feeling a sensation of vibration, 1.8% reported abdominal pain and 0.64% reported diarrhea.
Conclusions: In a community setting, the VC appears both effective and safe for long term treatment of chronic constipation with diarrhea being notably uncommon.
期刊介绍:
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.